Capital investments are ramping up in biomanufacturing, which continues to be an active area for CDMOs/CMOs in both traditional biologics and new modalities. Which companies are expanding?
Key topics: (see Chapter Markers in drop down menu in audio player above)
- A roundup of expansion activity (1:12)
- Fujifilm Diosynth Biotechnologies (1:21)
- Samsung Biologics (5:02)
- Lonza (6:44)
- Boehringer Ingelheim (10:00)
- Thermo Fisher Scientific (10:37)
- Catalent (13:59)
- WuXi Biologics (17:32)
Sponsor: BIOVECTRA
Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
